Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment
Condition: Histiocytosis Intervention: Drug: Trametinib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment
Condition: Histiocytosis Intervention: Drug: Trametinib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment
Condition: Histiocytosis Intervention: Drug: Trametinib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment
Condition: Histiocytosis Intervention: Drug: Trametinib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Condition: Histiocytosis Intervention: Drug: fluorodeoxyglucose (18F-FDG) Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
